• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Saliva and plasma concentrations of isoniazid and acetylisoniazid in man.人体中异烟肼和乙酰异烟肼的唾液及血浆浓度
Br J Clin Pharmacol. 1988 May;25(5):585-9. doi: 10.1111/j.1365-2125.1988.tb03349.x.
2
A simple method for determining acetylator phenotype using isoniazid.一种使用异烟肼测定乙酰化酶表型的简单方法。
Br J Clin Pharmacol. 1986 Sep;22(3):343-5. doi: 10.1111/j.1365-2125.1986.tb02897.x.
3
A single sample saliva test to determine acetylator phenotype.一种用于确定乙酰化酶表型的单样本唾液检测。
Br J Clin Pharmacol. 1996 Nov;42(5):635-7. doi: 10.1111/j.1365-2125.1996.tb00121.x.
4
[Application of a method of analysis using high performance liquid chromatography of isoniazid and acetylisoniazid to determine the phenotype of acetylation].
Ann Biol Clin (Paris). 1988;46(9):734-40.
5
A study of the effects of rifabutin on isoniazid pharmacokinetics and metabolism in healthy volunteers.
Drug Metabol Drug Interact. 1992;10(4):323-40. doi: 10.1515/dmdi.1992.10.4.323.
6
Isoniazid pharmacokinetics in children according to acetylator phenotype.
Fundam Clin Pharmacol. 2001 Oct;15(5):355-9. doi: 10.1046/j.1472-8206.2001.00044.x.
7
Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.以异烟肼作为代谢探针测定摩洛哥结核病患者的乙酰化表型。
Int J Clin Pharmacol Ther. 2002 Dec;40(12):548-53. doi: 10.5414/cpp40548.
8
Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.健康志愿者中异烟肼、乙酰异烟肼和异烟酸的群体药代动力学分析。
Antimicrob Agents Chemother. 2015 Nov;59(11):6791-9. doi: 10.1128/AAC.01244-15. Epub 2015 Aug 17.
9
The effects of acute ethanol intake on isoniazid pharmacokinetics.急性乙醇摄入对异烟肼药代动力学的影响。
Eur J Clin Pharmacol. 2004 Nov;60(9):679-82. doi: 10.1007/s00228-004-0828-y. Epub 2004 Oct 2.
10
Determination of isoniazid half-life from salivary samples.从唾液样本中测定异烟肼半衰期。
Int J Clin Pharmacol Ther Toxicol. 1986 Jan;24(1):18-22.

引用本文的文献

1
Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.结核病中的基因变异与药物疗效:迈向个性化治疗的一步。
Glob Med Genet. 2022 Feb 25;9(2):90-96. doi: 10.1055/s-0042-1743567. eCollection 2022 Jun.
2
PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.基于 PBPK 模型分析 NAT2 基因多态性对异烟肼药物相互作用潜力的影响
Pharm Res. 2021 Sep;38(9):1485-1496. doi: 10.1007/s11095-021-03095-9. Epub 2021 Sep 13.
3
Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.抗结核药物唾液浓度与血液浓度及其唾液治疗药物监测潜力的系统评价。
Ther Drug Monit. 2018 Feb;40(1):17-37. doi: 10.1097/FTD.0000000000000462.
4
Isoniazid metabolism and hepatotoxicity.异烟肼代谢与肝毒性。
Acta Pharm Sin B. 2016 Sep;6(5):384-392. doi: 10.1016/j.apsb.2016.07.014. Epub 2016 Aug 3.
5
pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice.pH响应性负载异烟肼纳米颗粒显著改善小鼠结核病治疗效果。
Small. 2015 Oct;11(38):5066-78. doi: 10.1002/smll.201500937. Epub 2015 Jul 20.
6
The effects of acute ethanol intake on isoniazid pharmacokinetics.急性乙醇摄入对异烟肼药代动力学的影响。
Eur J Clin Pharmacol. 2004 Nov;60(9):679-82. doi: 10.1007/s00228-004-0828-y. Epub 2004 Oct 2.
7
Drug acetylation in breast cancer.乳腺癌中的药物乙酰化作用。
Br J Cancer. 1989 Aug;60(2):236-7. doi: 10.1038/bjc.1989.260.
8
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.肾功能受损患者抗生素的临床药代动力学
Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002.

本文引用的文献

1
A method to prevent the loss of isoniazid and acetylisoniazid in human plasma.一种防止人血浆中异烟肼和乙酰异烟肼损失的方法。
Br J Clin Pharmacol. 1983 Feb;15(2):263-6. doi: 10.1111/j.1365-2125.1983.tb01496.x.
2
High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids.
J Chromatogr. 1983 Oct 14;277:385-90. doi: 10.1016/s0378-4347(00)84863-x.
3
Pharmacokinetics of tolbutamide: prediction by concentration in saliva.甲苯磺丁脲的药代动力学:通过唾液浓度进行预测。
Clin Pharmacol Ther. 1974 Dec;16(6):1052-8. doi: 10.1002/cpt19741661052.
4
A simple method for determining acetylator phenotype using isoniazid.一种使用异烟肼测定乙酰化酶表型的简单方法。
Br J Clin Pharmacol. 1986 Sep;22(3):343-5. doi: 10.1111/j.1365-2125.1986.tb02897.x.
5
Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects.
J Pharmacokinet Biopharm. 1975 Dec;3(6):443-56. doi: 10.1007/BF01059476.
6
Clinical pharmacokinetics of isoniazid.异烟肼的临床药代动力学
Clin Pharmacokinet. 1979 Nov-Dec;4(6):401-22. doi: 10.2165/00003088-197904060-00001.

人体中异烟肼和乙酰异烟肼的唾液及血浆浓度

Saliva and plasma concentrations of isoniazid and acetylisoniazid in man.

作者信息

Hutchings A D, Monie R D, Spragg B P, Routledge P A

机构信息

Department of Toxicology, Llandough Hospital, Penarth, South Glamorgan.

出版信息

Br J Clin Pharmacol. 1988 May;25(5):585-9. doi: 10.1111/j.1365-2125.1988.tb03349.x.

DOI:10.1111/j.1365-2125.1988.tb03349.x
PMID:3408638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1386432/
Abstract
  1. The pharmacokinetics of isoniazid and acetylisoniazid in plasma and saliva were compared following administration of oral and intravenous doses (200 mg) to healthy volunteers and patients. 2. In the 22 subjects studied after oral administration and the six subjects studied after intravenous administration there was complete phenotypic agreement for both slow (t1/2 greater than 130 min) and fast (t1/2 less than 130 min) acetylators using either saliva or plasma. 3. Acetylator phenotyping based on the t1/2 of INH determined using saliva collected at 2, 3, 4, 5 and 6 h after a 200 mg oral dose appears to be as reliable as that based on plasma. 4. Salivary isoniazid concentrations may provide a non-invasive alternative to plasma concentrations.
摘要
  1. 对健康志愿者和患者口服及静脉注射(200毫克)剂量后,比较了异烟肼和乙酰异烟肼在血浆和唾液中的药代动力学。2. 在口服给药后研究的22名受试者和静脉给药后研究的6名受试者中,使用唾液或血浆时,慢乙酰化者(t1/2大于130分钟)和快乙酰化者(t1/2小于130分钟)的表型完全一致。3. 根据口服200毫克剂量后2、3、4、5和6小时收集的唾液测定的异烟肼t1/2进行乙酰化者表型分析,似乎与基于血浆的分析一样可靠。4. 唾液中异烟肼浓度可能为血浆浓度提供一种非侵入性替代方法。